impassion130: implications
Published 4 years ago • 50 plays • Length 1:00Download video MP4
Download video MP3
Similar videos
-
2:30
impassion130: immunotherapy for tnbc
-
4:11
immunotherapy for tnbc: impassion130 & keynote-355
-
2:51
impassion130: design and preliminary efficacy
-
2:52
impassion130 study: improvement in os and pfs for iit and pd-l1 populations with mtnbc
-
4:46
performance of pd-l1 ihc assays in impassion130: a post-hoc analysis
-
4:20
keynote-522: 5-year follow-up of pembrolizumab in triple-negative breast cancer
-
7:42
the complexities of battling triple-negative breast cancer
-
14:35
what kind of cancer can be treated with immunotherapy? | apollo hospitals
-
5:53
immunohistochemistry (ihc) - video protocol series
-
2:24
keynote-355: pembrolizumab in triple-negative breast cancer
-
2:33
applying impassion130 data to tnbc management
-
1:15
clinical implications of progress in tnbc therapies
-
4:27
the impassion130 study in metastatic tnbc
-
0:41
the importance of brca-1 testing in triple negative breast cancer
-
7:08
impassion130: results of atezolizumab plus nab-paclitaxel for frontline tnbc
-
7:09
personalizing immunotherapy beyond pdl1 expression
-
5:59
impassion130: atezolizumab and nab-paclitaxel in triple-negative breast cancer
-
1:14
the importance of a biomarker-directed approach in triple-negative breast cancer
-
2:20
impassion130 and impassion131: the difference a taxane makes? | leisha emens
-
0:28
controversies in the treatment of the axilla
-
2:14
mechanism of action of eftilagimod alpha for the treatment of breast cancer
-
0:51
challenges in the treatment of mtnbc